Abstract
Currently, opiates are widely used as antitussives but have substantial side effects. Recently, it has been proposed that NOP1 receptor agonists may be useful as a novel approach to cough suppression. Therefore, we compared the effect of NOP1 receptor agonist SCH486757 with matched placebo and codeine in a multicentre, double-blind, parallel-group study in patients with subacute cough. The primary outcome was change in cough severity scores, with the key secondary outcome change in objective daytime cough counts. We studied 91 subjects with subacute cough [59 (65%) female, median age = 41 (range = 18–64) years, and median cough duration = 33 (range = 16–99) days]. Subjects were randomised to receive either SCH486757 100 mg, codeine 30 mg, or matched placebo twice daily for 5 days. Cough severity was scored throughout using a diary card and objective cough frequency recorded for 8 h at baseline and on the first and last treatment days. There were no significant differences in changes in average cough severity scores from baseline to treatment between SCH486757 and placebo [mean change = −0.57 (−30.1%) vs. mean change = −0.49 (−19.7%); P = 0.56] or between codeine and placebo [mean change = −0.72 (−33.2%); P = 0.07 compared to placebo). Changes in objective cough counts also showed no differences between the three treatment groups. There were some hints of possible limited antitussive efficacy with SCH486757. Unfortunately, the maximum clinical dose is limited by its tendency to produce somnolence. If the therapeutic ratio of NOP1 agonists could be improved, these drugs may still prove to contain effective antitussives.
Similar content being viewed by others
References
Morice AH, McGarvey L, Pavord I (2006) Recommendations for the management of cough in adults. Thorax 61(Suppl 1):i1–i24
Schappert SM, Burt CW (2006) Ambulatory care visits to physician offices, hospital outpatient departments, and emergency departments: United States, 2001–02. Vital Health Stat 13(159):1–66
Eccles R, Morris S, Jawad M (1992) Lack of effect of codeine in the treatment of cough associated with acute upper respiratory tract infection. J Clin Pharm Ther 17(3):175–180
Lee PCL, Jawad MS, Eccles R (2000) Antitussive efficacy of dextromethorphan in cough associated with acute upper respiratory tract infection. J Pharm Pharmacol 52(9):1137–1142
Lee PC, Jawad MS, Hull JD, West WH, Shaw K, Eccles R (2005) The antitussive effect of placebo treatment on cough associated with acute upper respiratory infection. Psychosom Med 67(2):314–317
McLeod RL, Parra LE, Mutter JC, Erickson CH, Carey GJ, Tulshian DB, Fawzi AB, Smith-Torhan A, Egan RW, Cuss FM, Hey JA (2001) Nociceptin inhibits cough in the guinea-pig by activation of ORL(1) receptors. Br J Pharmacol 132(6):1175–1178
McLeod RL, Tulshian DB, Hey JA (2003) Novel pharmacological targets and potential progression of new antitussive drugs. Expert Opin Therapeut Pat 13:1501–1512
McLeod RL, Tulshian DB, Ho GD, Fernandez X, Bolser DC, Parra LE, Zimmer JC, Erickson CH, Fawzi AB, Jayappa H, Lehr C, Erskine J, Smith-Torhan A, Zhang H, Hey JA (2009) Effect of a novel NOP receptor agonist (SCH 225288) on guinea pig irritant-evoked, feline mechanically induced and canine infectious tracheobronchitis cough. Pharmacology 84:153–161
Ho GD, Anthes J, Bercovici A, Caldwell JP, Cheng KC, Cui X, Fawzi A, Fernandez X, Greenlee WJ, Hey J, Korfmacher W, Lu SX, McLeod RL, Ng F, Torhan AS, Tan Z, Tulshian D, Varty GB, Xu X, Zhang H (2009) The discovery of tropane derivatives as nociceptin receptor ligands for the management of cough and anxiety. Bioorg Med Chem Lett 19(9):2519–2523
Yang SW, Ho G, Tulshian D, Greenlee WJ, Anthes J, Fernandez X, McLeod RL, Hey JA, Xu X (2009) Discovery of orally active 3-pyridinyl-tropane as a potent nociceptin receptor agonist for the management of cough. J Med Chem 52(17):5323–5329
Bunzow JR, Saez C, Mortrud M, Bouvier C, Williams JT, Low M, Grandy DK (1994) Molecular cloning and tissue distribution of a putative member of the rat opioid receptor gene family that is not a mu, delta or kappa opioid receptor type. FEBS Lett 347(2–3):284–288
Mollereau C, Parmentier M, Mailleux P, Butour JL, Moisand C, Chalon P, Caput D, Vassart G, Meunier JC (1994) ORL1, a novel member of the opioid receptor family. Cloning, functional expression and localization. FEBS Lett 341(1):33–38
Meunier JC, Mollereau C, Toll L, Suaudeau C, Moisand C, Alvinerie P, Butour JL, Guillemot JC, Ferrara P, Monsarrat B et al (1995) Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor. Nature 377(6549):532–535
Reinscheid RK, Nothacker HP, Bourson A, Ardati A, Henningsen RA, Bunzow JR, Grandy DK, Langen H, Monsma FJ Jr, Civelli O (1995) Orphanin FQ: a neuropeptide that activates an opioidlike G protein-coupled receptor. Science 270(5237):792–794
Calo G, Guerrini R, Rizzi A, Salvadori S, Regoli D (2000) Pharmacology of nociceptin and its receptor: a novel therapeutic target. Br J Pharmacol 129(7):1261–1283
Coyle MA, Keenan DB, Henderson LS, Watkins ML, Haumann BK, Mayleben DW, Wilson MG (2005) Evaluation of an ambulatory system for the quantification of cough frequency in patients with chronic obstructive pulmonary disease. Cough 1:3
Hoddes E, Zarcone V, Smythe H, Phillips R, Dement WC (1973) Quantification of sleepiness: a new approach. Psychophysiology 10(4):431–436
Nasra J, Belvisi MG (2009) Modulation of sensory nerve function and the cough reflex: understanding disease pathogenesis. Pharmacol Ther [Epub ahead of print]
Decalmer SC, Webster D, Kelsall AA, McGuinness K, Woodcock AA, Smith JA (2007) Chronic cough: how do cough reflex sensitivity and subjective assessments correlate with objective cough counts during ambulatory monitoring? Thorax 62(4):329–334
Bolser DC, McLeod RL, Tulshian DB, Hey JA (2001) Antitussive action of nociceptin in the cat. Eur J Pharmacol 430(1):107–111
Mazzone SB, Mori N, Canning BJ (2005) Synergistic interactions between airway afferent nerve subtypes regulating the cough reflex in guinea-pigs. J Physiol 569(Pt 2):559–573
Acknowledgments
The study sites were as follows: A.M. George, Cambridgeshire, UK; Philip Marazzi East Horsley, Surrey, UK; Lorcan McGarvey, Belfast, Northern Ireland, UK; Alyn Morice, Cottingham, UK; Moyra Anderson, Greenisland, Northern Ireland, UK; Thomas James Anthony Egerton, Bangor, County Down, Ireland; Anna M. E. Ker, Pretoria, South Africa; Fabian Galleguillos, Santiago, Chile; Monica Gutierrez, Vina Del Mar, Chile; Patricia Rivas, Rancagua, Chile; Tamara Soler, Santiago, Chile; Danelle C. Richter, Capetown South Africa; Nigel Gough, Wiltshire, UK.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Woodcock, A., McLeod, R.L., Sadeh, J. et al. The Efficacy of a NOP1 Agonist (SCH486757) in Subacute Cough. Lung 188 (Suppl 1), 47–52 (2010). https://doi.org/10.1007/s00408-009-9197-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00408-009-9197-8